B. Metzler seel. Sohn & Co. AG Invests $4.74 Million in Medpace Holdings, Inc. $MEDP

Key Points

• B. Metzler seel. Sohn & Co. AG purchased 8,944 Medpace shares worth approximately $4.74 million in the second quarter. Institutional investors collectively own 77.98% of the company.
• Medpace reported quarterly EPS of $4.25, exceeding the $3.98 analyst consensus, while revenue rose 17.2% year over year to $707.33 million. The company issued fiscal 2026 EPS guidance of $17.25–$17.95.
• Medpace shares opened at $620.75, near the upper end of their 52-week range, while analysts maintain a consensus “Hold” rating with a $584.18 price target. Insiders sold 122,261 shares worth roughly $71.7 million during the last quarter.

B. Metzler seel. Sohn & Co. AG purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 8,944 shares of the company's stock, valued at approximately $4,737,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. NewEdge Advisors LLC boosted its position in Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company's stock valued at $319,000 after acquiring an additional 190 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of Medpace by 3.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company's stock worth $24,929,000 after acquiring an additional 3,010 shares in the last quarter. Geneos Wealth Management Inc. lifted its stake in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after purchasing an additional 37 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in Medpace during the second quarter valued at about $296,000. Finally, M&T Bank Corp boosted its position in Medpace by 3.4% during the second quarter. M&T Bank Corp now owns 939 shares of the company's stock valued at $295,000 after purchasing an additional 31 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Stock Up 1.3%

Shares of NASDAQ MEDP opened at $620.75 on Friday. Medpace Holdings, Inc. has a 52 week low of $373.00 and a 52 week high of $677.90. The business's 50 day moving average price is $550.16 and its 200 day moving average price is $492.71. The firm has a market cap of $17.33 billion, a P/E ratio of 36.39, a P/E/G ratio of 2.73 and a beta of 1.15.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.98 by $0.27. The company had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. Medpace's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period last year, the firm posted $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts expect that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Insiders Place Their Bets

In other news, Director Brian T. Carley sold 5,000 shares of the stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the sale, the director directly owned 27,825 shares of the company's stock, valued at $16,935,129.75. This represents a 15.23% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Susan E. Burwig sold 7,500 shares of the firm's stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total value of $4,500,000.00. Following the sale, the vice president owned 62,984 shares in the company, valued at $37,790,400. This trade represents a 10.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 122,261 shares of company stock worth $71,729,129. Corporate insiders own 20.50% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on MEDP. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a $535.00 price objective on shares of Medpace in a research report on Thursday, July 23rd. Royal Bank Of Canada upped their price target on Medpace from $484.00 to $692.00 and gave the stock an "outperform" rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 price objective on Medpace in a report on Thursday, July 23rd. Robert W. Baird raised their price objective on Medpace from $547.00 to $624.00 and gave the stock a "neutral" rating in a research report on Friday, July 24th. Finally, Jefferies Financial Group cut Medpace from a "buy" rating to a "hold" rating and increased their price target for the company from $490.00 to $515.00 in a research note on Tuesday, July 7th. Three investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company's stock. According to data from MarketBeat, Medpace currently has a consensus rating of "Hold" and a consensus target price of $584.18.

Medpace Company Profile

Medpace Holdings, Inc NASDAQ: MEDP is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source